logo-loader
viewTelit Communications PLC

Telit says buyer of its automotive division expects to be in a position to complete transaction shortly

The buyer has indicated to Telit that it is required to (i) take certain administrative steps to comply with banking regulations in China and (ii) formalise financing arrangements for a part of the overall consideration

Cars
The AIM-listed group said the buyer has indicated it expects to satisfy these steps in the coming days

Telit Communications PLC (LON:TCM) rose on Thursday after the group said it expects the buyer of its automotive division, TUS International Limited to be in a position to complete the transaction shortly.

The global enabler of the Internet of Things (IoT), pointed out that, prior to completion, the buyer has indicated to Telit that it is required to (i) take certain administrative steps to comply with banking regulations in China and (ii) formalise financing arrangements for a part of the overall consideration.

READ: Telit up as IoT firm agrees to sale of automotive division for US$105mln

The AIM-listed group said the buyer has indicated it expects to satisfy these steps in the coming days.

It added: “The buyer has taken steps to provide the Board with comfort that it will be in a position to proceed to completion including having provided evidence of the availability of funds that remain subject to formal regulatory approval.”

Telit said on 27 December 2018, the timetable for the US$105mln cash acquisition of its automotive division by TUS was that it was expected to complete by 31 January 2019.

Initially, the transaction, announced at the end of July, was expected to complete by the end of 2018.

In afternoon trading on Thursday, Telit shares were 4.6% higher at 123.50p. Based on last night’s closing price, Telit’s market capitalisation was £154.94mln.

Quick facts: Telit Communications PLC

Price: 90.9 GBX

AIM:TCM
Market: AIM
Market Cap: £120.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn Get US FDA approval to move to FastTrack to Phase 2...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to discuss the company getting U.S. FDA  clearance to start a Phase 2 trial with leronlimab to treat COVID-19 patients with mild to moderate indications.  Pourhassan telling Proactive why they have been...

11 hours, 58 minutes ago

2 min read